Efficacy and QOL of switching from insulin glargine U100 or insulin deglidec to insulin glargine U300 in type2 diabetes mellitus

Efficacy and QOL of switching from insulin glargine U100 or insulin deglidec to insulin glargine U300 in type2 diabetes mellitus - Efficacy and QOL of switching from insulin glargine U100 or insulin deglidec to insulin glargine U300 in type2 diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031080

Enrollment

Registered

2018-01-31

Start date

2018-01-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

Insulin glargine U100 or insulin degludec will be administered daily for 12 weeks and switch from insulin glargine U100 or insulin deglidec to insulin glargine U300. The dosage of glargine U300 will

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes who is administered insulin glargine U100 or insulin degludec.

Exclusion criteria

Exclusion criteria: ?Cases of contraindications described in the package insert of insulin U100 or degldec or U300. ?Females who are or may be pregnant or lactating. ?Any other inadequacy for this study.

Design outcomes

Primary

Measure	Time frame
HbA1c, FPG, AGEs	—

Secondary

Measure	Time frame
Frequency of hypoglycemia , DTSQ	—

Countries

Japan

Contacts

Public ContactToru Kitazawa

Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Division of Diabetes, Endocrinology and Metabolism

cickkitazawa@gmail.com03-3823-2101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026